Our findings highlight the therapeutic relevance of B4GALT1 in PDAC, the feasibility of targeting aberrant glycosylation for anti-cancer therapy, and the translational potential of compound 1105486 as a new class of tumor-selective therapeutic agent for pancreatic cancer. This evidence concerns the gene B4GALT1 and familial pancreatic carcinoma.